Home |
About Us |
Investor Relations |
Products & Services |
Science & Technology |
People |
News & Events |
Contact Us
News |
Events
|
|
 |
|
||
 |
||
| |
|
 |
 |
| 10 October 2005 Directorate Changes Cyprotex PLC (AIM: CRX) ("Cyprotex" or the "Group"), the provider of pharmacokinetic technology and information, is pleased to announce the following two board changes to support the Group's future development. Nikolas Sofronis, aged 40, is appointed as a Non-executive Director of the Group with immediate effect. Over the last 15 years, Nikolas has worked within the biopharmaceuticals departments in several asset management organisations, including HSBC, Credit Lyonnais and the Republic Bank of New York. Nikolas is a graduate from the Athens Bar in Greece and is a lawyer by training. Dr. David Leahy will stand down from the board of Cyprotex to take up a new position heading Cyprotex Research Limited, a newly created wholly owned research facility of the Group. Cyprotex Research Limited will be charged with the further development of the Group's predictive technology capabilities. Commenting on these new appointments, Robert Morrisson Atwater, Chairman and Chief Executive Officer of Cyprotex, said: "The Directors would like to welcome Nikolas to the Board and at the same time thank David for his support and counsel over the last couple of years. We are delighted that Nikolas and David have taken up the challenge of these exciting new roles within the Group. I am sure that their contributions will both add significantly to the value of the enterprise." There are no further details to be announced pursuant to Schedule 2(g) of the AIM Rules for Companies. For further information: Cyprotex PLC Robert Morrisson Atwater, Chairman & Chief Executive Officer Tel: +44 1625 505 100 ir@cyprotex.com www.cyprotex.com Media Enquires: Abchurch Communications Heather Salmond Tel: +44 (0) 20 7398 7700 heather.salmond@abchurch-group.com www.abchurch-group.com |
|
|
 |
|
